APA (7th ed.) Citation

Al-Shamsi, H. O., Abdelwahed, N., Abdelwahab, S. I., Hussein, M., Abyad, A., Rafii, S., . . . Mokbel, K. (2026). Post-CDK4/6 Inhibitor Therapeutic Approaches in Hormone Receptor-Positive, HER2-Negative Metastatic Breast Cancer: Current Evidence and Emerging Strategies—A Narrative Review. Diagnostics (2075-4418), 16(12), 1790. https://doi.org/10.3390/diagnostics16121790

Chicago Style (17th ed.) Citation

Al-Shamsi, Humaid O., et al. "Post-CDK4/6 Inhibitor Therapeutic Approaches in Hormone Receptor-Positive, HER2-Negative Metastatic Breast Cancer: Current Evidence and Emerging Strategies—A Narrative Review." Diagnostics (2075-4418) 16, no. 12 (2026): 1790. https://doi.org/10.3390/diagnostics16121790.

MLA (9th ed.) Citation

Al-Shamsi, Humaid O., et al. "Post-CDK4/6 Inhibitor Therapeutic Approaches in Hormone Receptor-Positive, HER2-Negative Metastatic Breast Cancer: Current Evidence and Emerging Strategies—A Narrative Review." Diagnostics (2075-4418), vol. 16, no. 12, 2026, p. 1790, https://doi.org/10.3390/diagnostics16121790.